Cue Biopharma (CUE) Prix de l'Action, Cotation, Actualités et Historique | Benzinga

Cue Biopharma Inc (CUE) Prix de l'Action, Cotation, Actualités et Historique

CUENASDAQ

Trade with Public

Trade with Public

$16.71

-1.96-10.5%

Dern. MÀJ: Oct 16, 5:08 PM

$16.50

-2.17-11.62%

AperçuActualités Prévisions de résultats Événements Objectifs de cours Données financières Sentiment Actionnariat Comparer Rapport sur les stocks

© 2026 Benzinga | All Rights Reserved

Statistiques Clés

Ouverture

-

Clôture

$16.71

Volume / Moy.

83.00 / 270.08K

Fourchette Journalière

- - -

Plage 52 Sem.

4.97 - 45.50

Capitalisation Boursière

$119.86M

Ratio P/E

-

Rendement des Dividendes

-

Échange

NASDAQ

RSI

33

Intérêt à Découvert

10.15%

Jours pour Couvrir

1.05

Actualités Récentes de Cue Biopharma, Inc.

What's Going on With Cue Biopharma Stock on Monday?

Cue Biopharma reports Phase 2 CUE-221 trial results in chronic hives, showing strong efficacy and favorable safety.

Vandana Singh

Why Lobo Technologies Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket

Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.

Avi Kapoor

This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated bullish coverage on TRAX, BGSI, NPCE, CUE and NGVC, assigning Outperform/Buy ratings with price targets from $18 to $120.

Avi Kapoor

Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates, causing shares to jump 20.6% in pre-market trading. Other gainers include CUE, SST, AKAN, XXII, SDOT, TEAM, ISPC, and FIVN, while BAFN, RBLX, SKBL, and RNTX were among the losers.

Avi Kapoor

Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Cue Biopharma Inc. shares surged 67.57% after announcing a $30M financing, anti-IgE antibody license, and new CEO.

Mohd Haider

Données financières

Trimestriel

Annuel

Nom

Revenu Changement
Brut Changement
EBITDA Changement
EBIT Changement
Bénéfices Changement

Flux de Trésorerie

Flux de Trésorerie Opérationnel (TTM)

-50.05M

Flux de Trésorerie d'Investissement (TTM)

131.00K

Flux de Trésorerie de Financement (TTM)

39.82M

Flux de Trésorerie Libre (TTM)

-50.17M

Dépenses en Capital (TTM)

-121.00K

Variation Nette de la Trésorerie (TTM)

-10.10M

Tendances et prévisions des analystes

1

sept.

Acheter

Conserver

Vendre

Vente forte

Évaluation et prévisions des analystes

4.3

Acheter

Achat fort

Acheter

Conserver

Vendre

Vente forte

Métriques de Valorisation

Valeur Entreprise

$107.87M

Ratio P/E (TTM)

-

Ratio P/E (FWD)

-

Ratio PEG (TTM)

-

Ratio P/S (TTM)

2.02

Ratio P/B (TTM)

52.89

Rendement des Bénéfices % (TTM)

-175.15%

Rendement des Bénéfices % (FWD)

-

EV / EBITDA (TTM)

-

Prix / EBITDA (TTM)

-

Prix / Flux de Trésorerie Libre (TTM)

-

Valeur Comptable / Action

$0.32

Dette Entreprise

Dette Totale

-

Dette à Long Terme

-

Émission de Dette à Long Terme (TTM)

-

Remboursement de la Dette à Long Terme (TTM)

-$2.50M

Trésorerie Totale

$17.39M

Dette sur Capitaux Propres

1.33

Émission de Dette (TTM)

-$2.50M

Remboursement de la Dette (TTM)

-$2.50M